



## Optimizing Antimicrobial Use: Antimicrobial Stewardship and Surveillance

Guest Editor:

**Dr. Jesus Ruiz-Ramos**

Pharmacy Department, Hospital  
Santa Creu i Sant Pau. C./San  
Quintín 89, 08041 Barcelona,  
Spain

Deadline for manuscript  
submissions:

**15 December 2024**

### Message from the Guest Editor

Dear Colleagues,

During the last few decades, the implementation of antimicrobial stewardship programs has become more widespread in health centers. The objectives of these programs are to reduce the use of antimicrobials, reduce the duration of broad-spectrum antibiotic treatments, and to optimize individualized antibiotic treatment for the patient with the best efficacy and safety results, to slow down the advance of MDR pathogens. Even though there is ample evidence that the application of these multidisciplinary programs reduces the consumption of antimicrobials globally, the heterogeneity of the practices used and the unequal impact on the selection and infection by MDR strains make it essential to continue studying which interventions have a greater impact within these programs. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial stewardship programs' impact on bacterial resistance. Submissions on the impact of antimicrobial stewardship over bacterial resistance are especially encouraged.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)